Job Description
The National Cancer Institute (NCI) is seeking outstanding, internationally recognized and visionary scientists to lead independent research groups to conduct cutting-edge cancer research in the NCI Center for Cancer Research (CCR). All areas relevant to basic and translational cancer research will be considered, with a particular focus on cancer health disparities research. These positions are part of the National Institutes of Health’s (NIH) world-class intramural research program (IRP) and equivalent to a tenured academic associate professor or professor.
Successful candidates will be eligible to be appointed as an NIH tenured Senior Investigator and are expected to lead a world-class research program, supported by generous stable resources including access to a wide range of NCI technology platforms and interdisciplinary collaborations within NCI, as well as at NIH and its Clinical Center.
Qualifications and Job Details
Required and Preferred Skills
Successful candidates must possess an exceptional record of scientific achievement in cancer research, demonstrated leadership ability, proven effectiveness in mentoring and must meet the criteria for tenure at the NIH. In addition to being outstanding biomedical researchers, successful candidates will have a demonstrable commitment to, and track record of, promoting diversity and the inclusion of persons from underrepresented groups in biomedical research and they will actively contribute to achieve NCI’s institutional goals on diversity, equity, and inclusion.
About the NCI Center for Cancer Research
The Center for Cancer Research (CCR) is home to nearly 250 basic and clinical research groups located on two campuses just outside of Washington, D.C. CCR is part of the National Cancer Institute (NCI) and makes up the largest component of the research effort at the National Institutes of Health (NIH). Centrally supported by long-term funding and a culture of complete intellectual freedom, CCR scientists are able to pursue the most important and challenging problems in cancer research. We collaborate with academic and commercial partners and advocacy groups across the world in efforts to prevent, diagnose and treat cancer and HIV/AIDS. The CCR research portfolio covers the full spectrum of biological and biomedical research. Our work ranges from basic to translational and clinical, and our clinical trials are conducted in the NIH Clinical Center, the world’s largest hospital dedicated to clinical research that offers a robust infrastructure to support CCR’s patients on an estimated 250 open studies. The success of CCR is grounded in an exceptionally strong discovery research program that provides the foundation for the seamless translation of insights from bench to bedside. Read more about CCR, the benefits of working at CCR and hear from our staff on their CCR experiences.
Bethesda
Bethesda is one of the most highly educated communities in the United States and has a nationally renowned school system. The city is a thriving suburban center close to Washington, D.C., and home to many restaurants, retailers and a flourishing arts and entertainment district.
Frederick
Frederick is the second largest city in Maryland but retains a “small town” feel, surrounded by mountain views with a vibrant Main Street community. The city offers outstanding schools, a balanced and thriving economy and a highly educated workforce.
Include a diversity statement describing your track record of and commitment to diversity, equity, and inclusion in biomedical research and/or medicine, including but not limited to successful recruitment and/or mentorship of trainees from historically underrepresented groups, participation on committees and in programs/initiatives addressing issues of diversity and inclusion, and future plans for addressing diversity and inclusion as a principal investigator.
Applications must be submitted electronically to https://service.cancer.gov/ccr-careers. Review of applications will occur approximately every four months. The next review will occur on or about February 1, 2024.